← Leaderboards
John R Crouse
Wake Forest University
$7,936,079
Attributed
$7,936,079
Total exposure
43
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$7,936,079 · 43
By mechanism
M01$5,334,994 · 41
R01$2,601,085 · 2
Top collaborators
No co-investigators on record.
Most similar at Wake Forest University
Same institution · by research overlap
- Jay R Kaplan$8,821,281
- Robert P Byington$1,486,795
- David C Goff$21,680,129
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationInstitutionUnited States National Institutes Of HealthSourceGrantAntihypercholesterolemic AgentResourcesResearch PersonnelFundingComputer Retrieval Of Information On Scientific Projects DatabaseClinical TrialsEventHypercholesterolemiaDiabetes MellitusCardiovascular Disorder ChemotherapyParticipantMagnetic Resonance ImagingCoronary ArteriosclerosisDrug Administration Rate /DurationHmg Coa ReductasesBlood Pressure
Grant awards (69)
CLINICAL TRIAL: AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WIT$448,285
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)$129,812
M01 · FY2010 · RR · contact PI
AIM-HIGH CAROTID MRI STUDY$33,462
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WIT$407,332
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)$359,639
M01 · FY2009 · RR · contact PI
AIM-HIGH CAROTID MRI STUDY$14,600
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: CAROTID ATHEROSCLEROSIS (MRI) PROGRESSION STUDY (CAMPS)$7,300
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)$452,137
M01 · FY2008 · RR · contact PI
Carotid Atherosclerosis (MRI) Progression Study (CAMP)$324,303
R01 · FY2008 · HL · contact PI
CLINICAL TRIAL: AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WIT$230,194
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: CAROTID ATHEROSCLEROSIS (MRI) PROGRESSION STUDY (CAMPS)$85,161
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PREDICTING MICROALBUMINURIA IN TYPE 2 DIABETES ANCILLARY STUDY T$32,516
M01 · FY2008 · RR · contact PI
ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)$412,434
M01 · FY2007 · RR · contact PI
Carotid Atherosclerosis (MRI) Progression Study (CAMP)$393,425
R01 · FY2007 · HL · contact PI
AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WITH LOW HDL/HIGH$111,719
M01 · FY2007 · RR · contact PI
EFFECTS ON INTIMA MEDIA THICKNESS: ROSUVASTATIN 40 MG (METEOR)$5,739
M01 · FY2007 · RR · contact PI
CAROTID ATHEROSCLEROSIS (MRI) PROGRESSION STUDY (CAMPS)$3,090
M01 · FY2007 · RR · contact PI
ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)$490,563
M01 · FY2006 · RR · contact PI
Carotid Atherosclerosis (MRI) Progression Study (CAMP)$423,707
R01 · FY2006 · HL · contact PI
CAROTID ATHEROSCLEROSIS (MRI) PROGRESSION STUDY (CAMPS)$75,086
M01 · FY2006 · RR · contact PI
EFFECTS ON INTIMA MEDIA THICKNESS: ROSUVASTATIN 40 MG (METEOR)$46,417
M01 · FY2006 · RR · contact PI
EVALUATION OF SIMVASTATIN TREATMENT TO RETARD PROGRESS OF CORONARY CALCIFICATION$30,034
M01 · FY2006 · RR · contact PI
AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WITH LOW HDL/HIGH$1,365
M01 · FY2006 · RR · contact PI
ACCORD MEMORY IN DIABETES (MIND) SUB-STUDY$455
M01 · FY2006 · RR · contact PI
Carotid Atherosclerosis (MRI) Progression Study (CAMP)$450,874
R01 · FY2005 · HL
ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)$415,891
M01 · FY2005 · RR
EVALUATION OF SIMVASTATIN TREATMENT TO RETARD PROGRESS OF CORONARY CALCIFICATION$174,310
M01 · FY2005 · RR
EFFECTS ON INTIMA MEDIA THICKNESS: ROSUVASTATIN 40 MG (METEOR)$69,386
M01 · FY2005 · RR
CAROTID ATHEROSCLEROSIS (MRI) PROGRESSION STUDY (CAMPS)$25,808
M01 · FY2005 · RR
CASE CONTROL DIFFERENCES OF CAROTID ATHEROSCLEROSIS$4,230
M01 · FY2005 · RR
THE ANCILLARY EYE STUDY OF ACCORD$1,692
M01 · FY2005 · RR
CORONARY CALCIFICATION PROGRESSION STUDY$835
M01 · FY2005 · RR
Carotid Atherosclerosis (MRI) Progression Study (CAMP)$473,687
R01 · FY2004 · HL
Action to Control Cardiovascular Risks in Diabetes (ACCORD)$292,261
M01 · FY2004 · RR
Evaluation of Simvastatin Treatment to Retard Progress of Coronary Calcification$162,002
M01 · FY2004 · RR
Effects on Intima Media Thickness: Rosuvastatin 40 mg (METEOR)$92,312
M01 · FY2004 · RR
Azithromycin and Coronary Events Study (ACES)$34,297
M01 · FY2004 · RR
Coronary Calcification Progression Study$26,271
M01 · FY2004 · RR
Case Control Differences of Carotid Atherosclerosis$5,109
M01 · FY2004 · RR
Phase III Study Comparing Lovastatin XL 120 mg and Lipitor 20 mg$365
M01 · FY2004 · RR
Use of Helical Computed Tomography to Quantify Coronary Artery Lumen Stenosis$365
M01 · FY2004 · RR
8MG CERIVASTATIN VS 4MG CERIVASTATIN &PLACEBO &PRAVASTATIN IN HYPER$143,176
M01 · FY2002 · RR
CAROTID ARTERY FOLLOW UP STUDY (CAFUS)$143,176
M01 · FY2002 · RR
SIMVASTATIN &ATORVASTATIN IN PT W/ TYPE II DIABETES MELLITUS &HYPER$143,176
M01 · FY2002 · RR
ORAL &NUTRITIONAL TREATMENT OF LATE ONSET DIABETES$0
M01 · FY2002 · RR
TRIAL OF NICOSTATIN (COMB. NIACIN EXTENDED RELEASE/LOVA$0
M01 · FY2002 · RR
AZITHROMYCIN &CORONARY EVENTS STUDY (ACES): ANTIBIOTICS$0
M01 · FY2002 · RR
EFFICACY &SAFETY OF SIMVASTATIN VS ATORVASTATIN IN HYPERCHOLESTEROLE$0
M01 · FY2002 · RR
COLESEVELAM HCL &SIMVASTATIN IN PTS W/ PRIMARY HYPERCHOLESTEROLEMIA$0
M01 · FY2002 · RR
SIMVASTATIN ON POSTPRANDIAL HYPERLIPIDEMIA IN PTS W/ COMBINED HYPERLI$0
M01 · FY2002 · RR
METFORMIN AND PRAVACHOL IN TREATMENT OF DIABETIC DISLIPIDEMIA$0
M01 · FY2002 · RR
STUDY OF CHRONIC ADMINISTRATION OF CILOSTAZOL$0
M01 · FY2002 · RR
OPEN LABEL TRIAL OF NICOSTATIN (NIACIN /LOVASTATIN)$0
M01 · FY2002 · RR
TRIAL OF L-654969 &SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA$0
M01 · FY2002 · RR
CORONARY CALCIFICATION PROGRESSION STUDY$269,036
R01 · FY2001 · HL
CORONARY CALCIFICATION PROGRESSION STUDY$266,053
R01 · FY2000 · HL
METFORMIN AND PRAVACHOL IN TREATMENT OF DIABETIC DISLIPIDEMIA$38,800
M01 · FY2000 · RR
STUDY OF CHRONIC ADMINISTRATION OF CILOSTAZOL$38,800
M01 · FY2000 · RR
SIMVASTATIN &ATORVASTATIN IN PT W/ TYPE II DIABETES MELLITUS &HYPER$24,232
M01 · FY2000 · RR
EFFICACY &SAFETY OF SIMVASTATIN VS ATORVASTATIN IN HYPERCHOLESTEROLE$24,232
M01 · FY2000 · RR
COLESEVELAM HCL &SIMVASTATIN IN PTS W/ PRIMARY HYPERCHOLESTEROLEMIA$24,232
M01 · FY2000 · RR
SIMVASTATIN ON POSTPRANDIAL HYPERLIPIDEMIA IN PTS W/ COMBINED HYPERLI$24,232
M01 · FY2000 · RR
8MG CERIVASTATIN VS 4MG CERIVASTATIN &PLACEBO &PRAVASTATIN IN HYPER$24,232
M01 · FY2000 · RR
CAROTID ARTERY FOLLOW UP STUDY (CAFUS)$24,232
M01 · FY2000 · RR
ORAL &NUTRITIONAL TREATMENT OF LATE ONSET DIABETES$0
M01 · FY2000 · RR
TRIAL OF NICOSTATIN (COMB. NIACIN EXTENDED RELEASE/LOVA$0
M01 · FY2000 · RR
AZITHROMYCIN &CORONARY EVENTS STUDY (ACES): ANTIBIOTICS$0
M01 · FY2000 · RR
TRIAL OF L-654969 &SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA$0
M01 · FY2000 · RR
OPEN LABEL TRIAL OF NICOSTATIN (NIACIN /LOVASTATIN)$0
M01 · FY2000 · RR